OBJECTIVES: To compare initial and one year costs of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in the stent or surgery trial. DESIGN: Prospective, unblinded, randomised trial. SETTING: Multicentre study. PATIENTS: 988 patients with multivessel disease. INTERVENTIONS:CABG and stent assisted PCI. MAIN OUTCOME MEASURES: Initial hospitalisation and one year follow up costs. RESULTS: At one year mortality was 2.5% in the PCI arm and 0.8% in the CABG arm (p = 0.05). There was no difference in the composite of death or Qwave myocardial infarction (6.9% for PCI v 8.1% for CABG, p = 0.49). There were more repeat revascularisations with PCI (17.2% v 4.2% for CABG). There was no significant difference in utility between arms at six months or at one year. Quality adjusted life years were similar 0.6938 for PCI v 0.6954 for PCI, Delta = 0.00154, 95% confidence interval (CI) -0.0242 to 0.0273). Initial length of stay was longer with CABG (12.2 v 5.4 days with PCI, p < 0.0001) and initial hospitalisation costs were higher (7321 pounds sterling v 3884 pounds sterling for PCI, Delta = 3437 pounds sterling, 95% CI 3040 pounds sterling to 3848 pounds sterling). At one year the cost difference narrowed but costs remained higher for CABG (8905 pounds sterling v 6296 pounds sterling for PCI, Delta = 2609 pounds sterling, 95% CI 1769 pounds sterling to 3314 pounds sterling). CONCLUSIONS: Over one year, CABG was more expensive and offered greater survival than PCI but little added benefit in terms of quality adjusted life years. The additional cost of CABG can be justified only if it offers continuing benefit at no further increase in cost relative to PCI over several years.
RCT Entities:
OBJECTIVES: To compare initial and one year costs of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in the stent or surgery trial. DESIGN: Prospective, unblinded, randomised trial. SETTING: Multicentre study. PATIENTS: 988 patients with multivessel disease. INTERVENTIONS: CABG and stent assisted PCI. MAIN OUTCOME MEASURES: Initial hospitalisation and one year follow up costs. RESULTS: At one year mortality was 2.5% in the PCI arm and 0.8% in the CABG arm (p = 0.05). There was no difference in the composite of death or Q wave myocardial infarction (6.9% for PCI v 8.1% for CABG, p = 0.49). There were more repeat revascularisations with PCI (17.2% v 4.2% for CABG). There was no significant difference in utility between arms at six months or at one year. Quality adjusted life years were similar 0.6938 for PCI v 0.6954 for PCI, Delta = 0.00154, 95% confidence interval (CI) -0.0242 to 0.0273). Initial length of stay was longer with CABG (12.2 v 5.4 days with PCI, p < 0.0001) and initial hospitalisation costs were higher (7321 pounds sterling v 3884 pounds sterling for PCI, Delta = 3437 pounds sterling, 95% CI 3040 pounds sterling to 3848 pounds sterling). At one year the cost difference narrowed but costs remained higher for CABG (8905 pounds sterling v 6296 pounds sterling for PCI, Delta = 2609 pounds sterling, 95% CI 1769 pounds sterling to 3314 pounds sterling). CONCLUSIONS: Over one year, CABG was more expensive and offered greater survival than PCI but little added benefit in terms of quality adjusted life years. The additional cost of CABG can be justified only if it offers continuing benefit at no further increase in cost relative to PCI over several years.
Authors: J E Sousa; M A Costa; A Abizaid; A S Abizaid; F Feres; I M Pinto; A C Seixas; R Staico; L A Mattos; A G Sousa; R Falotico; J Jaeger; J J Popma; P W Serruys Journal: Circulation Date: 2001-01-16 Impact factor: 29.690
Authors: S B King; N J Lembo; W S Weintraub; A S Kosinski; H X Barnhart; M H Kutner; N P Alazraki; R A Guyton; X Q Zhao Journal: N Engl J Med Date: 1994-10-20 Impact factor: 91.245
Authors: M A Hlatky; W J Rogers; I Johnstone; D Boothroyd; M M Brooks; B Pitt; G Reeder; T Ryan; H Smith; P Whitlow; R Wiens; D B Mark Journal: N Engl J Med Date: 1997-01-09 Impact factor: 91.245
Authors: S J Pocock; R A Henderson; A F Rickards; J R Hampton; S B King; C W Hamm; J Puel; W Hueb; J J Goy; A Rodriguez Journal: Lancet Date: 1995-11-04 Impact factor: 79.321
Authors: P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: M J Sculpher; P Seed; R A Henderson; M J Buxton; S J Pocock; J Parker; M D Joy; E Sowton; J R Hampton Journal: Lancet Date: 1994-10-01 Impact factor: 79.321
Authors: Elizabeth A Magnuson; Michael E Farkouh; Valentin Fuster; Kaijun Wang; Katherine Vilain; Haiyan Li; Jaime Appelwick; Victoria Muratov; Lynn A Sleeper; Robin Boineau; Mouin Abdallah; David J Cohen Journal: Circulation Date: 2012-12-31 Impact factor: 29.690
Authors: Sara Michelly Gonçalves Brandão; Whady Hueb; Yang Ting Ju; Antonio Carlos Pedroso de Lima; Carisi Anne Polanczyk; Luciane Nascimento Cruz; Rosa Maria Rahmi Garcia; Myrthes Emy Takiuti; Edimar Alcides Bocchi Journal: Medicine (Baltimore) Date: 2017-12 Impact factor: 1.817
Authors: Stana Pačarić; Tajana Turk; Ivan Erić; Želimir Orkić; Anamarija Petek Erić; Andrea Milostić-Srb; Nikolina Farčić; Ivana Barać; Ana Nemčić Journal: Int J Environ Res Public Health Date: 2020-02-22 Impact factor: 3.390